Nanobiotix is trading 5.38% higher at $30.94 on October 26 after updated Phase 1 melanoma results were presented at the ESMO congress.
- In 24 heavily pretreated patients, the study reported a 41.7% response rate and median overall survival of 17.8 months.
- Coverage linked the rise to the data; the small, uncontrolled study remains preliminary, requiring further evaluation.
- The rally followed October 20, 21 and 22 gains; modestly positive index moves do not explain the company-specific rise.